Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.38 |
| ▸ | GAA | P10253 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | TACR1 | P25103 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | GFER | P55789 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25931762 | 0.79 | TACR1 (0.32) | TACR1 | |
| SCHEMBL22458516 | 0.78 | ALB (0.44) | ALDH1A1SMN1; SMN2GAALMNAKMT2A | |
| SCHEMBL26756418 | 0.78 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2GAALMNAKMT2A | |
| SCHEMBL5376196 | 0.77 | TACR1 (0.36) | ALDH1A1SMN1; SMN2LMNASIGMAR1TACR1 | |
| SCHEMBL12156552 | 0.77 | TACR1 (0.36) | ALDH1A1SMN1; SMN2LMNASIGMAR1TACR1 | |
| SCHEMBL12156565 | 0.77 | TACR1 (0.36) | ALDH1A1SMN1; SMN2LMNASIGMAR1TACR1 | |
| SCHEMBL8474356 | 0.76 | TSHR (0.43) | ALDH1A1SMN1; SMN2LMNAKMT2AMEN1 | |
| SCHEMBL21454264 | 0.76 | MEN1 (0.35) | SMN1; SMN2KMT2AMEN1SIGMAR1TACR1 | |
| SCHEMBL29589915 | 0.75 | SIGMAR1 (0.36) | KMT2AMEN1SIGMAR1MAPT | |
| SCHEMBL18538872 | 0.74 | APLNR (0.38) | KMT2AMEN1CACNA1HSIGMAR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230256121-A1 | DOTA-HAPTEN COMPOSITIONS FOR ANTI-DOTA/ANTI-TUMOR ANTIGEN BISPECIFIC ANTIBODY PRETARGETED RADIOIMMUNOTHERAPY | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2023-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230256121-A1 | DOTA-HAPTEN COMPOSITIONS FOR ANTI-DOTA/ANTI-TUMOR ANTIGEN BISPECIFIC ANTIBODY PRETARGETED RADIOIMMUNOTHERAPY | CD47, HLA-B, HLA-C | ALDH1A1 4575/4885SMN1; SMN2 4434/4885GAA 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.